| INTRODUC TI ON
Between 10-30% of patients with haemophilia A will develop antibodies to exogenous factor VIII, whilst only 2-5% of those with haemophilia B will develop antibodies to exogenous factor IX therapy. [1] [2] [3] The development of an inhibitor remains one of the most severe complications of replacement therapy in haemophilia patients.
The perspective with regard to surgical intervention in patients with haemophilia who have acquired antibody-mediated resistance to factor VIII and IX therapy has changed considerably over the last two decades. In orthopaedic surgery, with evidence suggesting not only an effective cost-benefit 4 but also significant quality of life improvements, [5] [6] [7] [8] there has been a shift from only considering emergency procedures to advising patients on elective surgery. 9 This paradigm shift is of special clinical significance to the inhibitor population.
One of the treatment goals in patients with haemophilia is to prevent haematoma formation in the synovium and cartilage, thereby avoiding a proclivity for haemophilic arthropathy. However, in those patients that develop antibodies to exogenous factor replacement, in the absence of newer agents that bypass the antibody inhibitors, haematoma formation is of greater risk. Unfortunately, treatments available for the control of acute bleeds are not as predictable as replacement therapy, and therefore, active bleeding is harder to control in the inhibitor population than non-inhibitor. 10 As such, this cohort often demonstrate more severe joint morbidity and hence significant orthopaedic disability. 11, 12 In 1956, De Palma and Cotler 13 considered it inadvisable to operate on patients with severe haemophilia. A decade later, a series by Ahlberg 14 
K E Y W O R D S
bleeding risk, FEIBA, haemophilia, inhibitors, orthopaedic surgery, rFVIIa as Robert Duthie. 15 Certainly, in elective orthopaedics, peri-and post-operative risks were significant. 16, 17 The advent of bypassing agents such as factor eight inhibitor bypassing agent (FEIBA; Baxter Bioscience, Vienna, Austria) and recombinant factor VIIa (rFVIIa;
NovoSeven, Novo Nordisk A/S, Bagsvaerd, Denmark) prevents bleeding in this treatment resistant group. These agents have now enabled surgery to be considered with increasing confidence, and this is reflected in the literature. 16, [18] [19] [20] [21] [22] [23] [24] [25] [26] Factor eight inhibitor bypassing agent is plasma-derived and primarily composed of four coagulation factors as follows: factor II (prothrombin), factor IX and factor X, which are chiefly in zymogen form, and factor VII, predominantly in the activated form. 27 The zymogenic FEIBA proteins support the haemostatic process by increasing the level of substrates available for activation by the appropriate enzymes, which are present in trace amounts within FEIBA.
The enzymes in FEIBA contribute to clot formation in the absence of FVIII or FIX through direct action and via the various feedback mechanisms.
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NovoSeven is a vitamin K-dependent glycoprotein and is structurally similar to human plasma-derived FVIIa. It acts by forming an extrinsic tenase complex with tissue factor expressed on cell surfaces at the site of injury. This then activates factor X, leading to thrombin generation and subsequent haemostasis. 28, 29 The first surgical procedure performed with NovoSeven was reported in 1988 by Hedner et al. 30 The authors described the successful synovectomy of the knee in a patient with inhibitors. Shortly thereafter, a seminal publication by Shaprio et al 21 described a randomized trial to assess the clinical safety and efficacy of NovoSeven. Consequently, following this early validation study, NovoSeven has been progressively utilized in the surgical management of inhibitor patients.
The general increased use and understanding of haematological factors have, over time, provided a concomitant growing body of evidence. The aforementioned humble pioneering beginnings in the form of case reports were followed by departmental and national reviews. The literature has culminated in the formation of international consensus groups. Parallel to these gains, orthopaedic surgeons have steadily developed guidance through multidisciplinary forums looking to optimize the outcome for their afflicted patients. As such, considering invasive procedures in haemophilia A or haemophilia B patients with factor VIII or IX antibodies, respectively, has moved on from the admonitory historic maxims of our prior opinion leaders.
However, caution persists, as those patients who have developed an inhibitor to factor VIII or IX remain rare, and their medical and surgical management continues to challenge those clinicians tasked.
Perhaps based on the literature's perceived inclination to field positive outcomes when faced with such a difficult cohort, there seems to be a mismatch between the face-value interpretation of published data and clinician experience. To the authors of this review, the personal experiences albeit anecdotal are more cautionary and in keeping with historic opinion. Certainly, the catastrophic consequences of infection are well known to any orthopaedic surgeon. The correlation between intra-and peri-operative bleeding and an increased risk of infection, of particularly grave consequence in arthroplasty, [31] [32] [33] [34] continues to be a focal point for improvement. 35 We have performed a scoping review of the literature describing major orthopaedic surgery in patients with inhibitors to summarize the key publications over the last two decades and provide perspective on numbers of patients, surgical procedures and bleeding complications.
We believe haemophilia patients with inhibitors remain very challenging, and from an orthopaedic perspective continue to pose a high bleeding complication rate due to the inherent nature of the condition. 41 Takedani et al publish in 2010 42 and subsequently in 2014 43 describing their 10-year experience. Caviglia et al published in 2011 44 and 2015. 45 The former encompasses a number of major orthopae- Details of the final 43 relevant studies are outlined in Table 1 .
| MATERIAL S AND ME THODS

| RE SULTS
The analysis of the pooled published data reveals that there were 317 cases of major orthopaedic surgery performed in 235 patients over the review inclusion period with a total of 129 individual bleeding complications, Table 1 .
The percentage rate of bleeding complications in major orthopaedic surgery is 40.7% (129 complications in 317 procedures).
In the assessment of bleeding complications as they relate to operative subgroups, the percentage of major orthopaedic procedures that experienced a bleeding complication was 30.6% (97 procedures experienced 1 or more complications in a total of 317 operations performed, Table 2 ).
In decreasing volume, knee arthroplasty (130 procedures, 
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In 1996 Ingerslev et al 39 published the first series of 12 patients with inhibitors undergoing major surgery. NovoSeven treatment was considered to be excellent in 11 patients. Following this series where bypassing agents were described as a "tempting alternative", agents such as NovoSeven and FEIBA have been subsequently deployed in a multitude of procedures.
In Ludlam et al's 46 prospective study observing NovoSeven continuous infusion during elective orthopaedic surgery, six of nine patients experienced in total 16 significant bleeding complications.
Four severe adverse events (3 operative site haemarthrosis, 1 anaemia requiring transfusion), 7 moderate adverse events (haemarthrosis), and 5 mild adverse events in one patient (incision site bleeding over an extended period of inpatient stay). The study concludes that major orthopaedic surgery can safely be carried out with continuous infusion of NovoSeven with bolus supplementation to reliably restore haemostasis.
In 2005, Goddard 47 presented our hospital's haemophilia centre experience, culminating in 78 joint replacements in 51 non-inhibitor patients, and two inhibitor patients undergoing a revision TKR in one, and a radial head excision followed by a primary knee replacement in the other. The primary TKR experienced a significant bleeding episode on day 3 post-operatively following dose reduction with a further less severe bleeding episode on day 12. This patient was hospitalized for a period of 3 weeks.
The haemostatic efficacy and safety of bolus vs continuous infusion NovoSeven has been tested in a randomized study 48 Over an 8-year period, 13 TKRs were performed on 8 male patients, all of whom had severe haemophilia with levels of factor <0.01 IU/ mL. There were three patients who had inhibitors to factor VIII.
As one patient had a staged bilateral procedure in the presence of The use of a hybrid regimen in major surgery was first described by van Veen et al 55 who concluded that although the overall outcome was good, their complication profile was higher than previously represented in the literature: four patients who underwent six TKRs, experiencing four bleeding complications all in the post-operative phase.
Ju et al 56 present one of the larger series involving 15 patients and 25 orthopaedic procedures. Only one patient was noted to have complications, they underwent two total knee replacements and required sequential bypassing therapy in one knee with a switch in therapy from NovoSeven to FEIBA in the other.
These two complications represent 8% of the orthopaedic cohort.
However, on detailed review of the results, six procedures in four patients required significant multiple red blood cell transfusions and/or a change in bypassing treatment. This increases the reportable and orthopaedically relevant bleeding complication rate from 8% to 24%. 
| D ISCUSS I ON
The advent of the bypassing agents has made previously impossi- Recent advances, however, such as thrombin generation assays can prove useful in assessing the balance between thrombin generation and decay in the presence of these inhibitors. 65 Currently, there are no widely agreed efficacy parameters that can be used to evaluate haemostatic response to bypassing agents during surgery. Agreement on such parameters would enable robust comparisons to be made between studies, rather than authors having to rely on qualitative assessments for bleeding. 44 In our review of the literature, it was not uncommon to find facevalue outcomes being described as effective or efficient haemostasis whilst a deeper analysis revealed continued or prolonged bleeding with or without the need for transfusion and the requirement of continued bypassing therapy. In part, the disparity between our collected data and conclusions drawn by original articles is a function of our definition criteria. There is no doubt, however, that many studies exist where significant blood loss requiring transfusion, increased dosing or a change in bypassing agent and/or surgery have not ultimately registered as an issue of global haemostatic efficacy.
Although thrombotic complications remain rare, bleeding complications in orthopaedic cases in particular are more frequent than had been previously thought.
This review has revealed multiple publications with duplications of prior series within their data set potentially confounding interpretation. In addition, given the inherent bias to report positive findings, it is likely that there has been a reluctance to publish treatment failures. In a number of studies, the post-operative follow-up has been relatively short and frequently measured by the ability to achieve haemostasis, rather than the formal assessment of any orthopaedic outcome measures.
Conversely, one must consider the high number of challenging cases reported, such as revision or pseudotumour surgery, which would influence bleeding complication rate independently of whether a patient was inhibitor positive or not. Interestingly, the data do not support such higher risk surgery being associated with a higher proportion of bleeding complications.
It is unfortunate, but understandable why, the type of thromboprophylaxis regimen used, or tourniquet use, is rarely mentioned. In Unfortunately, cost still remains a concern for both agents, and secondary to their invariable application, it is essential that the rescue treatments are accurately defined and included within protocols and therefore costing estimates. Furthermore, in keeping with considerations surrounding health economics and cost-effectiveness, certainly within orthopaedics, surgeons are increasingly mandated to report their outcomes. Rather than merely judging success by achieving haemostasis, such outcomes are often functional and frequently involve patient-reported outcome measures (PROMs).
With direct relevance to outcome, registries play an invaluable role in the management of many conditions and surgical interventions, and their importance is heightened in rare disorders. Key registries for haemophilia patients with inhibitors experiencing acute bleeds are running, collecting substantial post-approval data and have already changed practice. [67] [68] [69] The ONE registry revealed that fewer injections were required for bleeds treated with initial high doses, but that single and standard dose treatments were associated with similar overall effectiveness. 69 HemoRec, a prospective observational registry reported that higher initial doses and early treatment initiation of NovoSeven achieved a significantly faster bleed resolution. 68 The 
| CON CLUS ION
Ultimately, it is our collective professional and legal duty to patients with inhibitors, to ensure that the narrative surrounding major surgery is transparent and reflective of the realities. In so doing, we both engage with the autonomy of patients, whilst driving advances in the management of this challenging cohort of patients.
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